Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Change in Accured Expenses for 9 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 154.9% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 148.3% year-over-year, with the annual reading at $3.6 million for FY2025, 148.3% up from the prior year.
  • Change in Accured Expenses hit $3.2 million in Q4 2025 for Sutro Biopharma, up from -$6.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $27.1 million in Q4 2023 to a low of -$7.6 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $1.7 million across 5 years, with a median of $812500.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: soared 980.84% in 2021 and later plummeted 1237.35% in 2023.
  • Year by year, Change in Accured Expenses stood at $5.2 million in 2021, then dropped by 0.08% to $5.2 million in 2022, then surged by 417.35% to $27.1 million in 2023, then plummeted by 121.59% to -$5.8 million in 2024, then surged by 154.9% to $3.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for STRO at $3.2 million in Q4 2025, -$6.8 million in Q3 2025, and $8.5 million in Q2 2025.